The company is ramping up the launches of Orgovyx for prostate cancer and Myfembree for uterine fibroids, including indication and geographic expansions, and evaluating business development opportunities.
Having launched the gonadotropin-releasing hormone (GnRH) antagonist relugolix as Orgovyx for prostate cancer and Myfembree for the treatment of bleeding associated with uterine fibroids in the US in 2021, Myovant Sciences Ltd. is now focused on building commercially successful brands and establishing the next pillars for growth.
"These launches are off to a good start in 2021, and now we are looking for real growth as we...
Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
Oral RNA splicing modulator has gone into a Phase II/III trial
Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.
Oral RNA splicing modulator has gone into a Phase II/III trial
Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.
Government policy ramifications and tight financial markets mean it’s time to prepare strategically for a better business development environment, EY suggests.
